SEQUENCE LISTING

<110> SAIKAWA, Akira
       IGARI, Yasutaka
       YAMAMOTO, Yoshio
       HATA, Yoshio

<120> Sustained-Release Composition, Methods of its Preparation and Use
        Thereof

<130> 2500 US1P

<140> 10/799,320
<141> 2004-03-12

<150> US 09/582,926
<151> 2000-07-05

<150> PCT/JP99/00086
<151> 1999-01-13

<150> JP 10-6412
<151> 1998-01-16

<160> 5

<170> PatentIn version 3.2

<210> 1
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> DLeu, DAla, DTrp, DSer(tbut), D2Nal or DHis(ImBzl)

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Pro or Pro-NH-C2H5

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Gly-NH2 or nothing

1

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa
1   5   10

<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH antagonist derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N(4H2-furoyl)Gly or Nac

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D2Nal

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> D4ClPhe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> D3Pal

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> NMeTyr, Tyr, Aph(Atz) and NMeAph(Atz)

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur), DhArg(Et2),
      DAph(Atz), DhCi.

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Lys(Nisp), Arg, hArg(Et2).

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> DAlaNH2

<400> 2

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1   5   10

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Dleu

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Pro-NH-C2H5

<400> 3

Pro His Trp Ser Tyr Xaa Arg Pro
1   5

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-(S)-tetrahydrofur-2-oyl-Gly

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D2Nal

<220>
<221> MISC_FEATURE
<222> (3)..(3)

<223> D4ClPhe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> D3Pal

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> NmeTyr

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> DLys(Nic)

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Lys(Nisp)

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> DAlaNH2

<400> 4

Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1   5   10

<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Dleu

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Pro-NH-C2H5

<400> 5

Pro His Trp Ser Tyr Xaa Leu Arg Pro
1   5